GeneCentric Therapeutics Signify Research Collaboration to Assess Cancer Subtype Platform

Genecentric Therapeutics Inc. Proclaimed a research collaboration to assess the potential of Genecentric’s Cancer Subtype Platform in order to detect responders to G1 Therapeutic’s oral CDK4/6 inhibitor G1T38 for curing non- small cell lung cancer . As part of the research, Genecentric is set to apply its lung cancer subtyping profilers in patient- derived xenograft models to ascertain NSCLC subtype associations with G-1T38 response. The company will also evaluate potential drug response with certain genes. CSP, GeneCentric’s propriety core technology infers biologic subtypes of cancer through interpretation of tumor genomics. The subtypes have the capability to function as universal biomarkers of drug response  thus rendering more accuracy to to developing drugs. GeneCentric’s Lung Cancer Profilers (LSP 210 and LSP 220) define molecular subtypes of the two most common forms of NSCLC, adenocarcinoma and squamous cell carcinoma. Published studies have exhibited that the subtypes, while distinct by standard morphology, possess specific genetic, molecular and clinical attributes, and immune profiles that may yield drug response.